Novelia®
Novelia® is a multi-dose closing tip system which avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment.
Discover moreOphthalmic devices
A clear vision for eye care
One of the main criticalities of self-administered eye care treatments today is poor patient adherence, especially with chronic diseases.
We strive to improve patient experience by providing safe and effective multidose eyedroppers for preservative-free solutions, used all over the world.
e-Novelia
e-Novelia is the smart ophthalmic add-on which improves an already existing way of administrating ophthalmic treatments, to improve patients' adherence.
Discover moreOur services
Integrated services from device selection to GMP manufacturing
We have developed end-to-end services and expertise in ophthalmic device development, and device consulting, to complement our diverse portfolio of products to help you through every step of the journey.
Early-stage Innovation
Nemera provides a full understanding of the patient journey and recommends user-related activities to further optimize patients’ experience for a specific drug/device combination product.
Testing services for customer formulations
Thanks to our high-end laboratory facilities, we propose device plus formulation test services, as well as test methods development for our customers’ needs.
FAQs
Our systems are predominantly used for chronic pathologies requiring long-term daily use of eye drops, such as glaucoma, dry eye disease (DED), conjunctivitis, and allergies.
- Glaucoma is a group of eye diseases which result in damage to the optic nerve and cause vision loss, being a leading cause of global irreversible blindness. Overall, the results demonstrate that glaucoma is responsible for approximately 5.2 million cases of blindness (15% of the total burden of world blindness).
- Dry Eye Disease is a common multifactorial disease of the ocular surface with loss of homeostasis of the tear film and ocular symptoms, such as irritation, redness, discharge, and easily fatigued eyes. In epidemiological studies performed globally, the prevalence of dry eye disease (DED) ranges from 5 to 50 percent.
During Novelia®’s development phase, several user tests were conducted to ensure that patients understood how to effectively use the device.
One test revealed that some patients had difficulties seeing where the drop was coming from as it emerged from the dropper. This was because the dropper valve was transparent and thus hindered patients when targeting the eye. Consequently, the valve was changed from transparent to blue, providing an obvious contrast between the dropper tip and rest of the top.
Novelia®’s patented blue tip continues to be a key driver of patient preference for the dropper, allowing for enhanced eye targeting and patient control.
The alternative way to keep eye droppers free from contamination is by the intelligent use of technology. Rather than relying on the anti-microbial properties of preservatives to kill any bacteria that enter the bottle, the ideal approach is to prevent any entry of bacteria into the bottle in the first place.
Novelia® features a one-way valve the ensures that no contaminated liquid can be re-introduced into the container after a drop has been dispensed, completely removing the need to filter the liquid. The intake of air into the dispenser takes place via a separate venting system with a silicone membrane referred to as PureFlow® technology. Contrary to other marketed devices relying on filtration technology, our patented PureFlow® technology is a continuous barrier of homogeneous material which guarantees the integrity of the system.
More about Nemera
Knowledge Hub
Cutting-edge insights, resources, press articles, and webinars to learn more about the holistic ecosystem of drug delivery device solutions.
Discover moreWho we are
We design and manufacture devices that maximize treatment efficacy and partner with our customers in their device strategies, to ultimately bring high-quality and safe treatment solutions to patients.
Discover more